Samsung Biologics to invest $736m to build new drug manufacturing plant in South Korea

The facility, which will be built next to the company’s two existing plants, will have 180,000 liters of capacity.

The company said in a filing that it expects to complete the construction of the new facility by September 2018.

Samsung Biologics is already operating a multiproduct biologics facility, located on reclaimed land near Incheon international airport in South Korea.

The facility features stainless steel bioreactors with total capacity of 30,000 liters. It was designed and built to support high protein production.

It houses suites for upstream, downstream, fill & finish, an administration building, as well as a warehouse including longterm cold storage capacity.

Samsung Biologics is a joint venture established in April 2011 between Samsung Electronics, Samsung Everland, Samsung C&T and Quintiles Transnational.

The company provides a range of mammalian cell based cGMP biologics manufacturing services for clinical and commercial supply.

Headquartered in Incheon, Samsung BioLogics has plans to expand globally. The company plans to invest KRW2.1trn ($1.96bn) to strengthen its position in the field of biopharmaceuticals.

In 2013, the company secured contracts to manufacture biologic drugs for pharmaceutical companies Bristol-Myers Squibb and Roche.

Image: Samsung BioLogics broke ground on its first manufacturing plant in 2011. Photo: Copyright © 2014 SAMSUNG.